Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, to...

Related Keywords

United States ,Netherlands ,Cambridge ,Cambridgeshire ,United Kingdom ,American , ,Twitter ,Early Access Program ,Drug Administration ,Eu Press ,Exchange Commission ,American Society Of Clinical Oncology Annual Meetings ,Linkedin ,Breakthrough Therapy Designation ,Fast Track Designation ,Orphan Drug Designation ,Clinical Oncology Annual Meetings ,Biologics License Application ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,